Literature DB >> 3883355

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

A N Houghton, D Mintzer, C Cordon-Cardo, S Welt, B Fliegel, S Vadhan, E Carswell, M R Melamed, H F Oettgen, L J Old.   

Abstract

R24 is an IgG3 mouse monoclonal antibody that identifies GD3, a prominent ganglioside on the surface of melanoma cells and other cells of neuroectodermal origin. Twelve patients with metastatic melanoma were treated with R24 at three dose levels, 8, 80, or 240 mg/m2, over a period of 2 weeks. Peak antibody levels in the serum were dose related and ranged from less than 0.1 to 62 micrograms/ml. Inflammatory reactions (urticaria, pruritus, erythema, subcutaneous ecchymoses) were observed around tumor sites in patients treated at doses greater than or equal to 80 mg/m2. Tumor biopsies during and after treatment showed lymphocyte and mast cell infiltration, mast cell degranulation, and complement deposition. Side effects were mild and were readily controlled by antihistamines. Major tumor regression has been observed in three patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883355      PMCID: PMC397231          DOI: 10.1073/pnas.82.4.1242

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  8 in total

1.  Anaphylatoxin-mediated regulation of human and murine immune responses.

Authors:  E L Morgan; W O Weigle; T E Hugli
Journal:  Fed Proc       Date:  1984-07

2.  Serological analysis of cell surface antigens of malignant human brain tumors.

Authors:  M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

3.  Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.

Authors:  W G Dippold; A Knuth; K H Meyer zum Büschenfelde
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

4.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors:  W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

5.  Histogenesis of benign pleomorphic adenoma (mixed tumor) of the major salivary glands. An ultrastructural and immunohistochemical study.

Authors:  R A Erlandson; C Cardon-Cardo; P J Higgins
Journal:  Am J Surg Pathol       Date:  1984-11       Impact factor: 6.394

6.  Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.

Authors:  A N Houghton; M Eisinger; A P Albino; J G Cairncross; L J Old
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

7.  GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.

Authors:  C S Pukel; K O Lloyd; L R Travassos; W G Dippold; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

8.  Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.

Authors:  A N Houghton; H Brooks; R J Cote; M C Taormina; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

  8 in total
  114 in total

1.  Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; E Fonsatti; A Visintin; M Pavlovic; I Cattarossi; F Colizzi; A Gasparollo; S Coral; V Horejsi; M Altomonte; M Maio
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Immune recognition of self in immunity against cancer.

Authors:  Alan N Houghton; José A Guevara-Patiño
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

3.  Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies.

Authors:  D Scholz; M Lubeck; H Loibner; J McDonald-Smith; Y Kimoto; H Koprowski; Z Steplewski
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody.

Authors:  Stefan Stangl; Mathias Gehrmann; Julia Riegger; Kristin Kuhs; Isabelle Riederer; Wolfgang Sievert; Kathrin Hube; Ralph Mocikat; Ralf Dressel; Elisabeth Kremmer; Alan G Pockley; Lars Friedrich; Laszlo Vigh; Arne Skerra; Gabriele Multhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

5.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

Authors:  F Buchegger; C Pfister; K Fournier; F Prevel; M Schreyer; S Carrel; J P Mach
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

6.  Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Authors:  Brian H Kushner; Irene Y Cheung; Shakeel Modak; Kim Kramer; Govind Ragupathi; Nai-Kong V Cheung
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

7.  Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.

Authors:  M M Uttenreuther-Fischer; C S Huang; R A Reisfeld; A L Yu
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

8.  Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Authors:  K Kitamura; P O Livingston; S R Fortunato; E Stockert; F Helling; G Ritter; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas.

Authors:  K Bosslet; H F Kern; E J Kanzy; A Steinstraesser; A Schwarz; G Lüben; H U Schorlemmer; H H Sedlacek
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Monoclonal antibodies in detection of choroidal melanoma.

Authors:  P J Ringens; R van Haperen; C Vennegoor; P T de Jong; S G van Duinen; D J Ruiter; A W van der Kamp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.